Cara Therapeutics, a biopharmaceutical company focused on treating pruritus, has made significant strides in the development and commercialization of its therapeutics. The company's flagship product, KORSUVA (difelikefalin) injection, has shown promise in treating moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. Cara Therapeutics has also made notable progress in its product pipeline with Oral KORSUVA (difelikefalin), completing a Phase II clinical trial to treat pruritus in atopic dermatitis and non-dialysis-dependent chronic kidney disease associated pruritus, and currently in Phase II clinical trials to treat pruritus in chronic liver disease primary biliary cholangitis and notalgia paresthetica. The biopharmaceutical company has entered into several license agreements to develop, manufacture, and commercialize drug products containing difelikefalin. These agreements include partnerships with Maruishi Pharmaceutical Co., Ltd, Vifor Fresenius Medical Care Renal Pharma Ltd., Winhealth Pharma, and Chong Kun Dang Pharmaceutical Corporation to provide acute pain and uremic pruritus treatment in Japan, co-develop and commercialize KORSUVA injection for adult patients undergoing hemodialysis in China, and develop, manufacture, and commercialize difelikefalin drug products in South Korea. Cara Therapeutics was founded in 2004 and is headquartered in Stamford, Connecticut. With its continuous focus on developing and commercializing effective therapeutics for pruritus, the company is expected to make further breakthroughs in the biopharmaceutical industry.